Ágnes Ruzsa

6.1k total citations
9 papers, 301 citations indexed

About

Ágnes Ruzsa is a scholar working on Pulmonary and Respiratory Medicine, Oncology and Surgery. According to data from OpenAlex, Ágnes Ruzsa has authored 9 papers receiving a total of 301 indexed citations (citations by other indexed papers that have themselves been cited), including 5 papers in Pulmonary and Respiratory Medicine, 5 papers in Oncology and 4 papers in Surgery. Recurrent topics in Ágnes Ruzsa's work include Advanced Breast Cancer Therapies (2 papers), Radiopharmaceutical Chemistry and Applications (2 papers) and Breast Cancer Treatment Studies (2 papers). Ágnes Ruzsa is often cited by papers focused on Advanced Breast Cancer Therapies (2 papers), Radiopharmaceutical Chemistry and Applications (2 papers) and Breast Cancer Treatment Studies (2 papers). Ágnes Ruzsa collaborates with scholars based in Hungary, Belgium and Czechia. Ágnes Ruzsa's co-authors include Paul M. Clément, Gábor Répássy, Per Soelberg Sørensen, Igor Lifirenko, Jean-Pascal Machiels, Tina Nielsen, Steen Lisby, Anna Székely, Katalin Varga and Mária Judit Molnár and has published in prestigious journals such as Journal of Clinical Oncology, The Lancet Oncology and Quality of Life Research.

In The Last Decade

Ágnes Ruzsa

8 papers receiving 294 citations

Peers

Countries citing papers authored by Ágnes Ruzsa

Since Specialization

Citations

This map shows the geographic impact of Ágnes Ruzsa's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Ágnes Ruzsa with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Ágnes Ruzsa more than expected).

Fields of papers citing papers by Ágnes Ruzsa

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Ágnes Ruzsa. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Ágnes Ruzsa. The network helps show where Ágnes Ruzsa may publish in the future.

Co-authorship network of co-authors of Ágnes Ruzsa

This figure shows the co-authorship network connecting the top 25 collaborators of Ágnes Ruzsa. A scholar is included among the top collaborators of Ágnes Ruzsa based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Ágnes Ruzsa. Ágnes Ruzsa is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

9 of 9 papers shown

#	Work	Indexed citations
1	Pathologic Complete Response Rates After Neoadjuvant Pertuzumab and Trastuzumab with Chemotherapy in Early Stage HER2-Positive Breast Cancer - Increasing Rates of Breast Conserving Surgery: A Real-World Experience 2021 ·Pathology & Oncology Research ·Katalin Boér, (unknown), László Landherr, Tibor Csőszi, (unknown), Ágnes Ruzsa, Zsolt Horváth, Barna Budai, Gábor Rubovszky	9
2	A Retrospective Analysis of the First 41 mCRPC Patients with Bone Pain Treated with Radium-223 at the National Institute of Oncology in Hungary 2017 ·Pathology & Oncology Research ·(unknown), István Sinkovics, Péter Ágoston, (unknown), (unknown), (unknown), Magdolna Dank, (unknown), (unknown), (unknown), (unknown), Ágnes Ruzsa, Lajos Géczi	4
3	[Experience with cabazitaxel therapy for patients with metastatic castrate resistant prostate cancer in Hungary]. 2017 ·PubMed ·(unknown), Katalin Boér, (unknown), Magdolna Dank, (unknown), (unknown), János Révész, Ágnes Ruzsa, Miklós Szűcs, (unknown), Mária Vas, (unknown)	1
4	Phase 2, open-label, 1:1 randomized controlled trial exploring the efficacy of EMD 1201081 in combination with cetuximab in second-line cetuximab-naïve patients with recurrent or metastatic squamous cell carcinoma of the head and neck (R/M SCCHN) 2014 ·Investigational New Drugs ·Ágnes Ruzsa, Mehmet Şen, Mark D. Evans, (unknown), Katalin Hidéghety, Sylvie Rottey, (unknown), Petra Holečková, Jérôme Fayette, Tibor Csőszi, J. Erfán, Ulf Forssmann, Thomas Goddemeier, Alice Bexon, Christopher M. Nutting, (unknown)	46
5	First-line bevacizumab-paclitaxel in 220 patients with metastatic breast cancer: results from the AVAREG study. 2014 ·PubMed ·Magdolna Dank, (unknown), Béla Pikó, László Mangel, József Erfán, (unknown), Ágnes Ruzsa, László Landherr	11
6	The influence of patients’ gender and education level on the incidence of chemotherapy-induced anticipatory nausea and vomiting 2013 ·Orvosi Hetilap ·Ágnes Ruzsa, (unknown), (unknown)	0
7	Zalutumumab plus best supportive care versus best supportive care alone in patients with recurrent or metastatic squamous-cell carcinoma of the head and neck after failure of platinum-based chemotherapy: an open-label, randomised phase 3 trial 2011 ·The Lancet Oncology ·Jean-Pascal Machiels, (unknown), Ágnes Ruzsa, Gábor Répássy, Igor Lifirenko, (unknown), Per Soelberg Sørensen, Tina Nielsen, Steen Lisby, Paul M. Clément	163
8	An open-label, randomized, phase III trial of zalutumumab, a human monoclonal EGF receptor (EGFr) antibody, versus best supportive care, in patients with noncurable squamous cell carcinoma (SCCHN) of the head and neck who have failed standard platinum-based chemotherapy (ZALUTE). 2010 ·Journal of Clinical Oncology ·J. H. Machiels, S. Subramanian, Ágnes Ruzsa, Gábor Répássy, (unknown), (unknown), Peter G. Sørensen, E. Ehrnrooth, O Baadsgaard, Paul M. Clément	12
9	Validation of the Hungarian Translation of Hospital Anxiety and Depression Scale 2006 ·Quality of Life Research ·(unknown), Anna Székely, (unknown), Mária Judit Molnár, (unknown), Ágnes Ruzsa, Katalin Varga, (unknown), (unknown)	55

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact